IL-7 binding proteins and their use in medical therapy
Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
1. An interleukin 7 (IL-7) binding protein or IL-7 binding fragment thereof comprising:
i) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 6;
ii) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 7;
iii) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 8;
iv) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 9;
v) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 10; and
vi) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 11.
2. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 1 , comprising a heavy chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 4 and a light chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 5.
3. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 2 , comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5.
4. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 1 , comprising a heavy chain having a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 2 and a light chain having a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 3.
5. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 4 , comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a light chain comprising the amino acid sequence of SEQ ID NO: 3.
6. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 1 , wherein the IL-7 binding protein is an antibody.
7. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 6 , wherein the antibody is a monoclonal antibody.
8. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 6 , wherein the antibody is isolated.
9. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 6 , wherein the antibody is humanized.
10. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 6 , wherein the antibody comprises an IgG1, or IgG4 Fc region.
11. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 10 , wherein the antibody comprises a human IgG1 heavy chain constant region.
12. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 11 , wherein the antibody comprises a human IgG1 heavy chain constant region having an alanine residue at position 235 and position 237 according to EU numbering.
13. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 1 , wherein the IL-7 binding protein or IL-7 binding fragment thereof binds to human IL-7.
14. A pharmaceutical composition comprising the IL-7 binding protein or IL-7 binding fragment thereof, of claim 1 , and a pharmaceutically acceptable carrier.
15. The pharmaceutical composition of claim 14 , further comprising at least one additional therapeutic agent.
16. A pre-filled syringe or autoinjector device comprising the IL-7 binding protein or IL-7 binding fragment thereof, of claim 1 .
17. A kit comprising:
(i) the IL-7 binding protein or IL-7 binding fragment thereof of claim 1 ; and
(ii) instructions for use.
18. The IL-7 binding protein or IL-7 binding fragment thereof, of claim 6 , wherein the antibody comprises a constant region such that the IL-7 binding protein has reduced ADCC and/or complement activation or effector functionality.
19. A pharmaceutical composition comprising the IL-7 binding protein or IL-7 binding fragment thereof, of claim 3 , and a pharmaceutically acceptable carrier.
20. A pharmaceutical composition comprising the IL-7 binding protein or IL-7 binding fragment thereof, of claim 5 , and a pharmaceutically acceptable carrier.